Latest news with #AstecLifesciences
Business Upturn
02-05-2025
- Business
- Business Upturn
Why are Godrej Agrovet shares falling 10% today? Know More
By Aditya Bhagchandani Published on May 2, 2025, 10:06 IST Shares of Godrej Agrovet Ltd plunged over 9% to ₹700.65 in Thursday's session, reacting sharply to its Q4 FY25 results. The stock emerged as the top loser on the Nifty 500 index, and is now down nearly 20% from its 52-week high of ₹877, touched in July last year. The steep fall was triggered by muted financial performance for the March quarter. Revenue, EBITDA, and margins remained flat year-on-year, falling short of investor expectations despite a 24% rise in overall profitability. This growth was largely driven by gains in the domestic crop protection business, vegetable oil division, and improved margins in animal feed. However, the company's subsidiary Astec Lifesciences reported another challenging quarter due to demand-supply imbalances, volume headwinds, and price pressures in both enterprise and contract manufacturing. In the animal feed segment, margins were flat, while the dairy division saw margin erosion due to higher procurement costs. Additionally, Godrej Foods' profitability took a hit from lower live bird prices and weaker volume in that category. Despite the poor show, 4 out of 6 analysts tracking the stock still maintain a 'buy' rating, indicating some long-term optimism. However, one analyst each has a 'hold' and a 'sell' recommendation, reflecting cautious near-term sentiment. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
24-04-2025
- Business
- Business Standard
Astec Life tumbles after Q4 net loss widens to Rs 16 cr
Astec Lifesciences dropped 2.73% to Rs 748.60 after the company's consolidated net loss widened to Rs 16.08 crore in Q4 FY25 as against a net loss of Rs 0.964 crore reported in Q4 FY24. Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025. Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year. EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24. Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review. On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24. N. B. Godrej, chairman of Astec LifeSciences, said, In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year. Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.
Business Standard
24-04-2025
- Business
- Business Standard
Astec Lifesciences reports consolidated net loss of Rs 16.09 crore in the March 2025 quarter
Sales decline 22.26% to Rs 119.53 crore Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 119.53153.75 -22 381.30458.18 -17 OPM % 4.638.27 - -17.36-1.29 - PBDT -4.088.08 PL -97.27-25.49 -282 PBT -15.66-0.93 -1584 -140.99-61.75 -128 NP -16.09-0.97 -1559 -134.75-46.93 -187
